The Learning Portal will be under maintenance Monday, 6 December between 6 AM and 5 PM EST. Portal functionality will be unavailable during this window.
We apologize for any inconvenience caused during this time.

  • FDA Oncology Team Provides Insight into Review Process, Advisory Committees, Oncology Development

    In an interview this weekend with Biocentury TV , four employees of the Office of Hematology and Oncology Products (OHOP) sat down to provide insight in to the office, tips for regulatory professionals and their respective takes on oncologic drug development with Biocentury TV 's Steve Usdin. Dr. Paul Kluetz, a clinical reviewer for OHOP rejected the notion that OHOP incentives are aligned against the approval of products, saying that "there is no incentive to appr...